Spectrum Pharma (SPPI) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to Spectrum Pharma (SPPI) Misses Q4 EPS by 4c

Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update

March 6, 2018 4:00 PM EST

Poziotinib: following promising interim results, the Company is actively enrolling NSCLC patients with exon 20 insertion mutation in a multi-center study. ROLONTIS (eflapegrastim): ADVANCE study recently met the primary efficacy endpoint; RECOVER study fully enrolled; BLA filing expected in Q4 2018. Q4 revenues were $28.6 million, including $27.9 million in product sales.

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and... More